The American Medical Association is joining forces with healthcare groups to urge policymakers to make changes to remove barriers to opioid addiction treatment.

Civica Rx, a not-for-profit drug company with $100 million in funding that aims to combat drug shortages, has inked its next deal with Exela Pharma Sciences to supply its membership of hospitals with sodium bicarbonate injections.

The rate of uninsured Americans in 2018 rose for the first time since the Affordable Care Act went into place, according to new data from the Census Bureau.

Technology giant Apple has announced three new medical studies it will be involved in with major names in the healthcare space, including leading academic and research institutions.

The reputation of the pharmaceutical industry is tanking among U.S. consumers, the latest Gallup poll reveals.

New gene therapies are carrying price tags in the millions, leaving insurers scrambling to figure out how to cover them and offer the treatments to enrollees, according to The Wall Street Journal.

Medicare Part D overpaid millions of dollars for prescription drugs that should have been covered by the Medicare Part A hospice benefit, according to a recent report from the Office of Inspector General (OIG), which conducted an audit from 2016 payments. In other words, CMS paid twice for the same drugs.

The world’s biggest retailer, Walmart, is taking a bigger step into the healthcare space by opening up a primary care clinic called Walmart Health located in Georgia. The news was first reported by CNBC.

More than 3,400 drugs saw price hikes in the first half of 2019, with the average increase being more than five times the rate of inflation, according to CVS Caremark.

In the U.S., heart disease has been the reigning top cause of death for a number of years, but cancer is quickly becoming the top killer in some high-income and upper-middle-income countries, according to a new study published in The Lancet.

CMS is updating its Medicare Plan Finder for the first time in a decade.

HHS will provide $23 million to drug manufacturer Merck to produce Ebola vaccine doses over the next year, the agency announced Aug. 21.